USE OF AMINO ACID SEQUENCES FROM MYCOBACTERIUM TUBERCULOSIS OR CORRESPONDING NUCLEIC ACIDS FOR DIAGNOSIS AND PREVENTION OF TUBERCULAR INFECTION, DIAGNOSTIC KIT AND VACCINE THEREFROM
The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
2.
COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT
Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides. Also disclosed are methods for predicting elimination of LD spirochetes in LD patients who have undergone LD treatment, by exposing whole blood samples from such subjects to peptides comprising specific T-cell epitope regions of Borrelia proteins that are expressed at different stages of Lyme disease, and confirming a lack of Borrelia-specific activated T-cells in the samples by the absence of a detectable T-cell immune response indicator (e.g., interferon-Y).
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The present disclosure provides methods, sets of substantially complementary double-stranded adapters, and kits for performing nucleic acid sequencing. The substantial complementary double-stranded adapters comprise fully complementary molecular tag regions but one or more mismatches in other regions. Such adapters are ligated to double-stranded target nucleic acids, the obtained ligation products are amplified, and the generated amplification products are sequenced. The methods according to the present disclosure allow both strands of double-stranded target nucleic acids to be sequenced from one end of the target nucleic acids.
Compositions and methods are provided for detection, diagnosis and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) and for characterization of SARS-CoV-2 antigen-specific T-cell immune responsiveness in COVID-19 patient samples, including in secondary in vitro immune response assays for long-lived anamnestic (memory) T-cell responses. Disclosed compositions and methods include a method that comprises contacting, in vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-γ) in response to stimulation by the Spike protein-derived peptides.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention concerns a method for isolating DNA molecules having a size above a certain cut-off value from a DNA-containing sample. The method comprises a) contacting the sample with an aqueous composition comprising beads with a negatively charged surface, a molecular crowding agent, a dissolved salt comprising at least one divalent metal cation, and optionally a buffer for a time sufficient to bind DNA to the surface of the beads; b) separating the beads with bound DNA from the remaining composition; c) optionally washing the beads; and d) optionally eluting the bound DNA from the beads; wherein the ratio of the concentration of salt to the concentration of beads in the aqueous composition in step a) is at a value where an increase in the ratio leads to an increase in said cut-off value.
The invention relates to methods of enriching for target nucleic acid molecules, More particularly, the methods of enriching for target nucleic acid molecules comprise binding target nucleic acid molecules in a sample with one or more first target endonucleases that are specific to a first locus of a target region of the target nucleic acid molecules, separating the target nucleic acid molecules from nontarget nucleic acid molecules in the sample, and binding the separated target nucleic acid molecules with one or more second target endonucleases that are specific to a second locus of the target region of the target nucleic acid molecules, and uses thereof.
The present disclosure provides methods for isolating nucleic acids from a sample, comprising: (a) contacting a sample, a lysate of the sample, a supernatant of the lysate, or a portion of the sample, the lysate or the supernatant with one or more first agents (e.g., protein precipitating agents) and one or more second agents (e.g., inhibitor removing agents) to generate a mixture, (b) separating the mixture of step (a) into a solid phase and a liquid phase, wherein the one or more second agents are primarily in the solid phase, and (c) isolating nucleic acids from the liquid phase of step (b). Compositions and kits useful in such methods are also disclosed. Further disclosed are methods, compositions and kits for preparing a lysate using a lytic reagent comprising one or more relatively mild chaotropic agents and one or more phosphates from a sample, especially a complex sample, such as a soil or stool sample.
Disclosed herein are methods for producing DNA libraries by incorporating dUTPs into DNA fragments and treating with uracil-DNA glycosylase and kits for preparing the DNA libraries. The DNA libraries are advantageous for next generation sequencing.
Disclosed herein are methods for producing DNA libraries by incorporating dUTPs into DNA fragments and treating with uracil-DNA glycosylase and kits for preparing the DNA libraries. The DNA libraries are advantageous for next generation sequencing.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
10.
PRIMERS WITH SELF-COMPLEMENTARY SEQUENCES FOR MULTIPLE DISPLACEMENT AMPLIFICATION
The present disclosure provides primers, primer sets, kits and methods for multiple displacement amplification, especially in combination with nucleic acid sequencing. The primers comprise self-complementary sequences at their 5′ termini and random or semi-random sequences at their 3′ termini. Use of such primers facilitates handling of multiple samples, increases sequence coverage uniformity, and improves sequencing error corrections.
in vitroin vitroin vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-γ) in response to stimulation by the Spike protein-derived peptides.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 7/04 - Peptides linéaires ne contenant que des liaisons peptidiques normales
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
12.
Methods of Detecting Analytes and Compositions Thereof
The invention relates to methods of detecting analytes in samples by generating analyte-based DNA libraries amenable for sequencing. The methods include the use of proximity probe pairs, each probe comprising an analyte binding domain and oligonucleotide domain. The methods further provide for integrated DNA and RNA library preparations and methods of making and uses thereof. The invention also provides compositions useful in the methods.
Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
14.
Methods for co-isolation of nucleic acids and proteins
Provided are methods for isolating biomolecules, such as nucleic acids and proteins, from a sample using a silica-containing surface and/or a high salt, low pH buffer.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
15.
Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
16.
Methods for Preparing CDNA Samples for RNA Sequencing, and CDNA Samples and Uses Thereof
The invention relates to methods for preparing cDNA samples for RNA sequencing using random priming oligonucleotides comprising a cell barcode (cID), a unique molecular index (UMI), and a random sequence region, and performing a reverse transcription reaction (RT). The invention also relates to cDNA samples prepared by the methods and uses thereof.
C12Q 1/6853 - Réactions d’amplification d’acides nucléiques utilisant des amorces ou des matrices modifiées
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
17.
METHODS OF ENRICHING FOR TARGET NUCELIC ACID MOLECULES AND USES THEREOF
The invention relates to methods of enriching for target nucleic acid molecules, More particularly, the methods of enriching for target nucleic acid molecules comprise binding target nucleic acid molecules in a sample with one or more first target endonucleases that are specific to a first locus of a target region of the target nucleic acid molecules, separating the target nucleic acid molecules from nontarget nucleic acid molecules in the sample, and binding the separated target nucleic acid molecules with one or more second target endonucleases that are specific to a second locus of the target region of the target nucleic acid molecules, and uses thereof.
The invention relates to methods of nucleic acid preparations. More specifically, the methods relate to obtaining a normalized quantity of target nucleic acid molecules from multiple samples for simultaneous analysis of the multiple samples, such as by sequencing.
The present disclosure provides methods and kits for inhibiting cDNA synthesis of unwanted RNA species during reverse transcription. The methods and kits provided herein use blocking oligonucleotides such as those comprising locked nucleic acids (LNAs).
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
20.
Small-molecule mediated size selection of nucleic acids
Provided are methods and compositions for negatively and positively selecting for different size nucleic acid (e.g., DNA or RNA) fragments on borosilicate glass fiber membranes, silica and metal oxide surfaces such that only those fragments falling within a desired size range are obtained.
The present disclosure provides methods and kits for highly multiplex single primer extensions using a MutS protein and Mg2+ at a concentration higher than that in a typical PCR reaction. Also disclosed is the use of such methods and kits in next generation sequencing.
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
Compositions and methods are disclosed that relate to protecting biological activity of a biologically active molecule, including a biologically active protein or biological response modifier such as an immune response modifier, against radiation damage during radiation sterilization. Inclusion of at least one radio-protectant compound, for example, cysteine, reduced glutathione, melatonin, and/or histidine, in an exemplary mitogenic lectin formulation during spray-drying onto surfaces of immunoassay tubes, surprisingly protected the lectin against loss of biological (mitogenic) activity that would otherwise result from electron beam radiation sterilization. The radioprotectant compound also protected other biologically active molecules and stabilized their biological activities, permitting them to retain biological activity after extended storage following the radiation treatment.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The present disclosure provides methods for isolating proteins and optionally nucleic acids from a sample, comprising: (a) contacting a sample, a lysate of the sample, a supernatant of the lysate, or a portion of the sample, the lysate or the supernatant with one or more first agents selected from low molecular weight carboxylates and sulfate and one or more second agents that are multivalent (e.g., trivalent) salt(s) to generate a mixture, (b) separating the mixture of step (a) into a solid phase and a liquid phase, wherein the one or more second agents are primarily in the solid phase, and (c) isolating proteins and optionally nucleic acids from the liquid phase of step (b). Compositions and kits useful in such methods are also disclosed.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes; non-medical reagents, enzymes and buffer solutions for scientific and/or medical research use; non-medical reagents, enzymes and buffer solutions for molecular biology scientific research applications; non-medical reagents, enzymes and buffer solutions for scientific research use for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits for scientific research use comprising chemicals for sample preparation, modification and manipulation of cells; kits for scientific research use comprising chemicals for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material; kits for scientific research use comprising reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; diagnostic chemical, biochemical and biotechnological preparations for medical and veterinary purposes, in particular reagents, enzymes and buffer solutions for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; diagnostic kits containing preparations for medical and veterinary diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing
25.
Integrative DNA and RNA library preparations and uses thereof
The invention relates to integrated DNA and RNA library preparations and methods of making and uses thereof, wherein the DNA molecules are labelled with a tag identifying the molecule as being a DNA molecule and the RNA molecules are labelled with a tag identifying the molecule as being a RNA molecule. The methods do not require physical separation of DNA and RNA. The methods output two separate libraries from DNA and RNA, respectively, which helps flexible manipulation on downstream sequencing platforms. The application also claims the DNA library and the cDNA library produced by the method and the DNA tag and the RNA tag used in the method.
Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
27.
METHODS AND USAGE FOR QUANTITATIVE EVALUATION OF CLONAL AMPLIFIED PRODUCTS AND SEQUENCING QUALITIES
This disclosure describes, in one aspect, a method and algorithm for quantitative evaluation clonal amplified products (for example, but not limited to, rolonies) and sequencing qualities (including sequencing chemistry and instrument) on solid surfaces (for example, flow cells). The sequencing data are processed by primary analysis software to generate files comprising FQ file, SAM file, FASTQ file, and surface map output and intensity files. The statistical data are extract from above files to generate a comprehensive evaluation matrix based on cluster size from each tile or selected tile subsets or all of the tiles, including the number of total cluster objects, mapped percentage, mapped quality (Qscores), mapped length, error rate, GC content, signal intensity, etc. The size distribution based statistical evaluation matrix can be applied for differentiation of root causes of sequencing quality variation, including clonal amplification quality and quantity, seeding conditions of clonal amplified products, sequencing chemistry quality and instrument variations.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure provides methods and kits for performing high multiplex PCR using molecular barcodes. The methods disclosed herein separately extend a set of primers (BC primers) that each comprise a molecular barcode and a target-specific sequence, and amplify the resulting extension products using another set of primers (LA primers) that each comprise another target-specific sequence. Such methods avoid barcode resampling and suppress primer dimers in traditional high multiplex PCR.
This invention relates in general to methods of sequencing multiple distinct and separate polynucleotide fragments and regions in a sequential order, such as on a flow cell surface. The invention provides methods that solve prior art problems with regard to sequential sequencing, and that provide advantages including low cost, shorter turn-around-time, high efficiency, and easy implementation.
The present disclosure provides compositions and methods for adaptor design and nucleic acid library construction for rolony-based sequencing. Also provided are kits for preparing a library of rolonies for sequencing.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
Produits et services
Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes; non-medical reagents, enzymes and buffer solutions for scientific and/or medical research use; non-medical reagents, enzymes and buffer solutions for molecular biology applications; non-medical reagents, enzymes and buffer solutions for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits comprising chemicals for sample preparation, modification and manipulation of cells; kits comprising chemicals for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material; kits comprising reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing. Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, in particular reagents, enzymes and buffer solutions for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits containing preparations for medical and veterinary diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing. Scientific apparatuses, instruments and devices, as well as their parts and components included in this class; software for use in scientific and medical research; scientific apparatuses, instruments and devices, software in the area of analysis of nucleic acids, in particular sequencing of nucleic acids.
Methods and compositions for enriching a population of particles containing an analyte are disclosed. In one embodiment, enrichment beads are used that are larger in size than the beads used for amplification. A separation device is employed that can retain larger beads with bound amplified beads. The technique finds many uses, including enriching for beads with clonally amplified template, which can be used in a variety of assays, including nucleic acid sequencing.
This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Modular flow cells, devices with modular flow cells, and methods of sequencing using modular flow cells, as well as systems and kits including modular flow cells, are described, permitting sequencing wherein less than the full capacity for sequencing is desired.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention is directed to a method for digital quantification of individual sample molecules in vitro without physically partitioning the reaction mixture and to a kit adapted for carrying out said method.
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
36.
METHODS OF DETECTING ANALYTES AND COMPOSITIONS THEREOF
The invention relates to methods of detecting analytes in samples by generating analyte-based DNA libraries amenable for sequencing. The methods include the use of proximity probe pairs, each probe comprising an analyte binding domain and oligonucleotide domain. The methods further provide for integrated DNA and RNA library preparations and methods of making and uses thereof. The invention also provides compositions useful in the methods.
The invention relates to methods for preparing cDNA samples for RNA sequencing using random priming oligonucleotides comprising a cell barcode (cID), a unique molecular index (UMI), and a random sequence region, and performing a reverse transcription reaction (RT). The invention also relates to cDNA samples prepared by the methods and uses thereof.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6853 - Réactions d’amplification d’acides nucléiques utilisant des amorces ou des matrices modifiées
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.
A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 5/078 - Cellules du sang ou du système immunitaire
The present disclosure provides methods and kits for inhibiting cDNA synthesis of unwanted RNA species during reverse transcription. The methods and kits provided herein use blocking oligonucleotides such as those comprising locked nucleic acids (LNAs).
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
Fiducial marking systems provided for forming a global coordinate system for a visual system having a limited field of view. The fiducial marking system includes a target surface that is movable relative to the visual system and a visual pattern associated with the target surface. The visual pattern includes a plurality of first lines and a plurality of second lines. Each first line is spaced by a first distance from each adjacent first line and each second line is spaced by a second distance from each adjacent second line, wherein the first distance is different than the second distance. Additionally, the first distance and the second distance are selected such that at least one first line and at least one second line are within the field of view at all relative positions of the visual system and the target surface.
Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
42.
PROTECTION OF BIOLOGICALLY ACTIVE MOLECULES DURING RADIATION STERILIZATION
Compositions and methods are disclosed that relate to protecting biological activity of a biologically active molecule, including a biologically active protein or biological response modifier such as an immune response modifier, against radiation damage during radiation sterilization. Inclusion of at least one radioprotectant compound, for example, cysteine, reduced glutathione, melatonin, and/or histidine, in an exemplary mitogenic lectin formulation during spray-drying onto surfaces of immunoassay tubes, surprisingly protected the lectin against loss of biological (mitogenic) activity that would otherwise result from electron beam radiation sterilization. The radioprotectant compound also protected other biologically active molecules and stabilized their biological activities, permitting them to retain biological activity after extended storage following the radiation treatment.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
43.
PROTECTION OF BIOLOGICALLY ACTIVE MOLECULES DURING RADIATION STERILIZATION
Compositions and methods are disclosed that relate to protecting biological activity of a biologically active molecule, including a biologically active protein or biological response modifier such as an immune response modifier, against radiation damage during radiation sterilization. Inclusion of at least one radioprotectant compound, for example, cysteine, reduced glutathione, melatonin, and/or histidine, in an exemplary mitogenic lectin formulation during spray-drying onto surfaces of immunoassay tubes, surprisingly protected the lectin against loss of biological (mitogenic) activity that would otherwise result from electron beam radiation sterilization. The radioprotectant compound also protected other biologically active molecules and stabilized their biological activities, permitting them to retain biological activity after extended storage following the radiation treatment.
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
44.
NUCLEIC ACID ISOLATION AND INHIBITOR REMOVAL FROM COMPLEX SAMPLES
The present disclosure provides methods for isolating nucleic acids from a sample, comprising: (a) contacting a sample, a lysate of the sample, a supernatant of the lysate, or a portion of the sample, the lysate or the supernatant with one or more first agents (e.g., protein precipitating agents) and one or more second agents (e.g., inhibitor removing agents) to generate a mixture, (b) separating the mixture of step (a) into a solid phase and a liquid phase, wherein the one or more second agents are primarily in the solid phase, and (c) isolating nucleic acids from the liquid phase of step (b). Compositions and kits useful in such methods are also disclosed. Further disclosed are methods, compositions and kits for preparing a lysate using a lytic reagent comprising one or more relatively mild chaotropic agents and one or more phosphates from a sample, especially a complex sample, such as a soil or stool sample.
The present disclosure provides methods for isolating nucleic acids from a sample, comprising: (a) contacting a sample, a lysate of the sample, a supernatant of the lysate, or a portion of the sample, the lysate or the supernatant with one or more first agents (e.g., protein precipitating agents) and one or more second agents (e.g., inhibitor removing agents) to generate a mixture, (b) separating the mixture of step (a) into a solid phase and a liquid phase, wherein the one or more second agents are primarily in the solid phase, and (c) isolating nucleic acids from the liquid phase of step (b). Compositions and kits useful in such methods are also disclosed. Further disclosed are methods, compositions and kits for preparing a lysate using a lytic reagent comprising one or more relatively mild chaotropic agents and one or more phosphates from a sample, especially a complex sample, such as a soil or stool sample.
The present disclosure provides methods for isolating proteins and optionally nucleic acids from a sample, comprising: (a) contacting a sample, a lysate of the sample, a supernatant of the lysate, or a portion of the sample, the lysate or the supernatant with one or more first agents selected from low molecular weight carboxylates and sulfate and one or more second agents that are multivalent (e.g., trivalent) salt(s) to generate a mixture, (b) separating the mixture of step (a) into a solid phase and a liquid phase, wherein the one or more second agents are primarily in the solid phase, and (c) isolating proteins and optionally nucleic acids from the liquid phase of step (b). Compositions and kits useful in such methods are also disclosed.
Disclosed are compositions and methods for determining the nucleotide sequence of sequences of interest using paired-end sequencing. Dumbell circular templates can be generated and used in a rolling circle amplification reaction by ligating two hairpin adaptors on a double-stranded amplicon. Disclosed also are methods using double-stranded DNA, including both sense and antisense strands in a single circle to sequence, sequentially from the same concatemers.
The invention relates to integrated DNA and RNA library preparations and methods of making and uses thereof, wherein the DNA molecules are labelled with a tag identifying the molecule as being a DNA molecule and the RNA molecules are labelled with a tag identifying the molecule as being a RNA molecule. The methods do not require physical separation of DNA and RNA. The methods output two separate libraries from DNA and RNA, respectively, which helps flexible manipulation on downstream sequencing platforms. The application also claims the DNA library and the cDNA library produced by the method and the DNA tag and the RNA tag used in the method.
Methods and compositions for enriching a population of particles containing an analyte are disclosed. In one embodiment, enrichment beads are used that are larger in size than the beads used for amplification. A separation device is employed that can retain larger beads with bound amplified beads. The technique finds many uses, including enriching for beads with clonally amplified template, which can be used in a variety of assays, including nucleic acid sequencing.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
51.
DNA quality assessments using repetitive sequences
The present disclosure provides methods, arrays and kits for assessing the quality of genomic DNA samples, especially those obtained from formalin-fixed paraffin-embedded (FFPE) samples. The methods, arrays and kits provided herein use primer pairs specific to regions in the genomes of the organisms from which genomic DNA samples are obtained that have identical or nearly identical copies distributed across multiple chromosomes.
The present disclosure provides methods, sets of substantially complementary double-stranded adapters, and kits for performing nucleic acid sequencing. The substantial complementary double-stranded adapters comprise fully complementary molecular tag regions but one or more mismatches in other regions. Such adapters are ligated to double-stranded target nucleic acids, the obtained ligation products are amplified, and the generated amplification products are sequenced. The methods according to the present disclosure allow both strands of double-stranded target nucleic acids to be sequenced from one end of the target nucleic acids.
The present-invention provides methods, compositions, mixtures and kits utilizing 5-Chloro-2-methyl-4-isothiazolin-3-one in sequencing reactions, and in particular, sequencing reactions where deoxynucleoside triphosphates comprising a 3'-O position capped by a disulfide-based 3'-terminator group are used. In one embodiment, the deoxynucleoside triphosphates comprise a 3'-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
A flowcell device for a sequencing by synthesis instrument. The flowcell device has a fluid inlet configured to receive one or more liquid reagents, a fluid outlet configured to pass the one or more liquid reagents, and a channel extending between and fluidly connecting the fluid inlet and the fluid outlet. At least a portion of the channel comprises a reflective structure configured to retain a plurality of sequencing targets thereon. The reflective structure includes at Ieast a metal oxide layer and a film having a first surface and a second surface opposed the first surface. The first surface of the film is disposed on the metal oxide layer and the second surface of the film is configured to receive a plurality of sequencing targets immobilized thereon.
A microfluidic device with a microfluidic circuit including an array of fluidly coupled microchambers. Each microchamber includes a reaction chamber and an associated vent chamber. The microfluidic circuit may be arranged so that a fluid sample introduced to microfluidic device flows into the reaction chamber and air or other gas present in the reaction chamber is vented from the microchamber through the vent chamber. The microchamber may be configured to allow only the flow of air into the vent chamber from the reaction chamber until the air has been displaced from the reaction chamber by the fluid sample and/or a predefined volume of the fluid sample has been received in the reaction chamber. The microchamber may be further configured to release the fluid sample to thereafter flow from the reaction chamber into the vent chamber.
B01J 19/26 - Réacteurs du type à injecteur, c.-à-d. dans lesquels la distribution des réactifs de départ dans le réacteur est effectuée par introduction ou injection au moyen d'injecteurs
A microfluidic device with a microfluidic circuit including an array of fluidly coupled microchambers. Each microchamber includes a reaction chamber and an associated vent chamber. The microfluidic circuit may be arranged so that a fluid sample introduced to microfluidic device flows into the reaction chamber and air or other gas present in the reaction chamber is vented from the microchamber through the vent chamber. The microchamber may be configured to allow only the flow of air into the vent chamber from the reaction chamber until the air has been displaced from the reaction chamber by the fluid sample and/or a predefined volume of the fluid sample has been received in the reaction chamber. The microchamber may be further configured to release the fluid sample to thereafter flow from the reaction chamber into the vent chamber.
A microfluidic device with a microfluidic circuit including an array of fluidly coupled microchambers. Each microchamber includes a reaction chamber and an associated vent chamber. The microfluidic circuit may be arranged so that a fluid sample introduced to microfluidic device flows into the reaction chamber and air or other gas present in the reaction chamber is vented from the microchamber through the vent chamber. The microchamber may be configured to allow only the flow of air into the vent chamber from the reaction chamber until the air has been displaced from the reaction chamber by the fluid sample and/or a predefined volume of the fluid sample has been received in the reaction chamber. The microchamber may be further configured to release the fluid sample to thereafter flow from the reaction chamber into the vent chamber.
The present disclosure provides oligonucleotides that comprise semi-random barcode sequences. Such oligonucleotides may be incorporated into reverse transcription primers, PCR primers, or portions of sequencing adapters in preparing sequencing libraries. The resulting sequencing libraries can be used for accurate sequencing, including DNA or RNA counting and mutation detection. Methods and kits for preparing sequencing adapters and sequencing libraries are also provided.
The present disclosure provides primers, primer sets, kits and methods for multiple displacement amplification, especially in combination with nucleic acid sequencing. The primers comprise self-complementary sequences at their 5′ termini and random or semi-random sequences at their 3′ termini. Use of such primers facilitates handling of multiple samples, increases sequence coverage uniformity, and improves sequencing error corrections.
Provided are methods for isolating biomolecules, such as nucleic acids and proteins, from a sample using a silica-containing surface and/or a high salt, low pH buffer.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
61.
Methods and kits for highly multiplex single primer extension
The present disclosure provides methods and kits for highly multiplex single primer extensions using a MutS protein and Mg2+ at a concentration higher than that in a typical PCR reaction. Also disclosed is the use of such methods and kits in next generation sequencing.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
Provided are methods and compositions for negatively and positively selecting for different size nucleic acid (e.g., DNA or RNA) fragments on borosilicate glass fiber membranes, silica and metal oxide surfaces such that only those fragments falling within a desired size range are obtained.
The present invention relates to a polymerase enzyme with improved ability to incorporate reversibly terminating nucleotides. The enzyme comprising the following mutations in the motif A region (SGS). It relates to a polymerase enzyme according to SEQ ID NO. 1 with mutations in the amino acid sequence positions 409, 410 and 411.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
The present invention relates to a polymerase enzyme from Pyrococcus furiosus with improved ability to incorporate reversibly terminating nucleotides. The enzyme comprising the following mutations in the motif A region (SGS). It relates to a polymerase enzyme according to SEQ ID NO. 1 or any polymerase that shares at least 70% amino acid sequence identity thereto, comprising a mutation selected from the group of (i) at position 409 of SEQ ID NO. 3: serine (S) (L409S) and/or, (ii) at position 410 of SEQ ID NO. 3: glycine (G) (Y410G) and/or (iii) at position 411 of SEQ ID NO. 3: serine (S) (P411S), wherein the enzyme has little or no 3'-5' exonuclease activity.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
The present invention relates to a polymerase enzyme from 9°N with improved ability to incorporate reversibly terminating nucleotides. The enzyme comprising mutations in the motif A region. The invention also relates to methods of using such enzymes as well as a kit with such polymerases.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
The present invention relates to a polymerase enzyme with improved ability to incorporate reversibly terminating nucleotides. The enzyme comprising the following mutations in the motif A region (SGS). It relates to a polymerase enzyme according to SEQ ID NO. 1 or any polymerase that shares at least 70% amino acid sequence identity thereto, comprising a mutation selected from the group of (i) at position 412 of SEQ ID NO. 1 : serine (S) (L412S) and/or, (ii) at position 413 of SEQ ID NO. 1: glycine (G) (Y413G) and/or (iii) at position 414 of SEQ ID NO. 1: serine (S) (P414S), wherein the enzyme has little or no 3'-5' exonuclease activity.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
67.
Mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
68.
DNA quality assessments using repetitive sequences
The present disclosure provides methods, arrays and kits for assessing the quality of genomic DNA samples, especially those obtained from formalin-fixed paraffin-embedded (FFPE) samples. The methods, arrays and kits provided herein use primer pairs specific to regions in the genomes of the organisms from which genomic DNA samples are obtained that have identical or nearly identical copies distributed across multiple chromosomes.
A method of determining risk of preterm labor in an asymptomatic pregnant woman can include: obtaining a vaginal fluid sample from an asymptomatic pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determined risk to the pregnant woman. When the PAMG-1-antibody complex forms, the asymptomatic pregnant woman is determined to be susceptible to preterm labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the asymptomatic pregnant woman is determined to be not susceptible to preterm labor because the PAMG-1 is not detected in the vaginal sample.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A method of determining suitability of a pregnant woman to be a candidate for induction of labor can include: obtaining a vaginal fluid sample from a pregnant woman; contacting the vaginal fluid sample with a PAMG-1 antibody that binds with PAMG-1; detecting whether the PAMG-1 antibody binds with PAMG-1 in the vaginal fluid sample to form a PAMG-1-antibody complex; and providing the determination of suitability for induction of labor to the pregnant woman. When the PAMG-1-antibody complex forms, the pregnant woman is determined to be in a condition that is not suitable for induction of labor because PAMG-1 is detected in the vaginal sample. When the PAMG-1-antibody complex does not form, the pregnant woman is determined to be in a condition that is suitable to be a candidate for induction of labor because the PAMG-1 is not detected in the vaginal sample.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
71.
Methods for predicting time-to-delivery in pregnant women
The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
72.
ANTIOXIDANT COMPOUNDS FOR CLEAVE FORMULATIONS THAT SUPPORT LONG READS IN SEQUENCING-BY-SYNTHESIS
Methods, compositions, devices, systems and kits are described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. Higher base reads with lower error rates are achieved with the use of Ascorbic Acid (AA), also known as Vitamin C, as an antioxidant additive to the cleave reagent.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
73.
PHOTOPROTECTIVE MIXTURES AS IMAGING REAGENTS IN SEQUENCING-BY-SYNTHESIS
The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of photoprotective mixture of compounds as imaging reagents to improve stability and storage of fluorescent compounds, including but not limited to, nucleotides with fluorescent labels.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
74.
ENHANCING SEQUENCING PERFORMANCE IN SEQUENCING-BY-SYNTHESIS
The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis (SBS) methods. In particular, the present invention contemplates the use of chelators in washing reagents to improve SBS performance.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
75.
THIOL-CONTAINING CLEAVE REAGENTS AND OXIDATIVE WASH
The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3'-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure provides methods, sets of substantially complementary double-stranded adapters, and kits for performing nucleic acid sequencing. The substantial complementary double-stranded adapters comprise fully complementary molecular tag regions but one or more mismatches in other regions. Such adapters are ligated to double-stranded target nucleic acids, the obtained ligation products are amplified, and the generated amplification products are sequenced. The methods according to the present disclosure allow both strands of double-stranded target nucleic acids to be sequenced from one end of the target nucleic acids.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure provides methods and kits for performing high multiplex PCR using molecular barcodes. The methods disclosed herein separately extend a set of primers (BC primers) that each comprise a target-specific sequence, a molecular barcode and a universal sequence, and amplify the resulting extension products using another set of primers (LA primers) that each comprise another target-specific sequence and a universal sequence. The methods may further comprise amplification using universal primers (preferably comprising an adapter).
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
The present disclosure provides primers, primer sets, kits and methods for multiple displacement amplification, especially in combination with nucleic acid sequencing. The primers comprise self-complementary sequences at their 5' termini and random or semi-random sequences at their 3' termini. Use of such primers facilitates handling of multiple samples, increases sequence coverage uniformity, and improves sequencing error corrections.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
79.
ADDITIVE TO IMPROVE SEQUENCING BY SYNTHESIS PERFORMANCE
The invention relates to methods, compositions, devices, systems and kits are described including, without limitation, reagents and mixtures, for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
81.
FLOWCELLS WITH MICRORETAINERS FOR DISCRETE SEEDING MICROSPOTS
A flowcell for a sequencing instrument. The flowcell includes a fluid inlet, a fluid outlet, a flow channel formed between an at least partially transparent cover and a base and fluidly connecting the fluid inlet to the fluid outlet, and a capture substrate provided in the flow channel. The capture substrate includes microretainers configured to each receive a single microspot having a microspot diameter, and microretainer is separated from adjacent microretainers by an interstitial gap distance that is equal to or greater than the microspot diameter. A particle separator may be fluidly connected to the flowcell. The particle separator may include a microfluidic channel having an array of micropillars to transfer a plurality of the microspots to a loading buffer that may be delivered to the flowcell.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 33/483 - Analyse physique de matériau biologique
G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p. ex. analyse à injection dans un écoulement
A sequencing instrument including a sequencing stage and a microscope. The sequencing stage has a reference plate with a flat reference surface. The microscope optical axis is perpendicular to the reference surface. The sequencing stage is configured to receive a flexible film having a plurality of DNA templates immobilized on a first side of the film, and to hold the flexible film against the flat reference surface with at least some of the plurality of DNA templates in an object plane that is perpendicular to the microscope's optical axis.
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
83.
Flowcells with microretainers and particle separators for discrete seeding microspots
A flowcell for a sequencing instrument. The flowcell includes a fluid inlet, a fluid outlet, a flow channel formed between an at least partially transparent cover and a base and fluidly connecting the fluid inlet to the fluid outlet, and a capture substrate provided in the flow channel. The capture substrate includes microretainers configured to each receive a single microspot having a microspot diameter, and microretainer is separated from adjacent microretainers by an interstitial gap distance that is equal to or greater than the microspot diameter. A particle separator may be fluidly connected to the flowcell. The particle separator may include a microfluidic channel having an array of micropillars to transfer a plurality of the microspots to a loading buffer that may be delivered to the flowcell.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p. ex. analyse à injection dans un écoulement
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
84.
LABELED DEOXYNUCLEOSIDE TRIPHOSPHATES, USES THEREOF AND METHODS FOR THEIR PREPARATION
The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3'-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
C07H 19/20 - Radicaux purine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A DNA flow cell processing method including positioning the flow cell on a stage at a predetermined location relative to a camera, illuminating the flow cell from a side with a first light source to reflect light off the DNA fragment bead locations, obtaining a first image of the flow cell and identifying a first reference pattern of bead locations in the first image, moving at least one of the flow cell and the stage relative to the camera, attempting to reposition the stage at the predetermined location, obtaining a second image of the flow cell, identifying the first reference pattern in the second image, and evaluating a first offset, relative to the camera, between the first reference pattern in the first image and the first reference pattern in the second image.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
H04N 7/18 - Systèmes de télévision en circuit fermé [CCTV], c.-à-d. systèmes dans lesquels le signal vidéo n'est pas diffusé
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
G02B 21/10 - Condensateurs donnant un éclairage sur fond noir
G02B 21/16 - Microscopes adaptés pour éclairage ultraviolet
G02B 21/36 - Microscopes aménagés pour la photographie ou la projection
G01N 15/00 - Recherche de caractéristiques de particulesRecherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3'-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure provides methods and kits for highly multiplex single primer extensions using a MutS protein and Mg2+ at a concentration higher than that in a typical PCR reaction. Also disclosed is the use of such methods and kits in next generation sequencing.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
88.
COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT
Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides. Also disclosed are methods for predicting elimination of LD spirochetes in LD patients who have undergone LD treatment, by exposing whole blood samples from such subjects to peptides comprising specific T-cell epitope regions of Borrelia proteins that are expressed at different stages of Lyme disease, and confirming a lack of Borrelia-specific activated T-cells in the samples by the absence of a detectable T-cell immune response indicator (e.g., interferon-Y).
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
89.
COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT
Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides. Also disclosed are methods for predicting elimination of LD spirochetes in LD patients who have undergone LD treatment, by exposing whole blood samples from such subjects to peptides comprising specific T-cell epitope regions of Borrelia proteins that are expressed at different stages of Lyme disease, and confirming a lack of Borrelia-specific activated T-cells in the samples by the absence of a detectable T-cell immune response indicator (e.g., interferon-Y).
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
90.
METHODS FOR CO-ISOLATION OF NUCELIC ACIDS AND PROTEINS
Provided are methods for isolating biomolecules, such as nucleic acids and proteins, from a sample using a silica-containing surface and/or a high salt, low pH buffer.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
91.
SMALL-MOLECULE MEDIATED SIZE SELECTION OF NUCLEIC ACIDS
Provided are methods and compositions for negatively and positively selecting for different size nucleic acid (e.g., DNA or RNA) fragments on borosilicate glass fiber membranes, silica and metal oxide surfaces such that only those fragments falling within a desired size range are obtained.
The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
93.
Methods for predicting time-to-delivery in pregnant women
The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
The present disclosure provides methods and kits for performing high multiplex PCR using molecular barcodes. The methods disclosed herein separately extend a set of primers (BC primers) that each comprise a target - specific sequence, a molecular barcode and a universal sequence, and amplify the resulting extension products using another set of primers (LA primers) that each comprise another target - specific sequence and a universal sequence. The methods may further comprise amplification using universal primers (preferably comprising an adapter).
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
Subject of the invention is a composition comprising at least one fragment of the peptide ESAT-6 and at least one fragment of the peptide CFP-10. Preferably, the fragments comprise at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater. The invention also relates to diagnostic methods using the composition.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
The present disclosure provides oligonucleotides that comprise semi-random barcode sequences. Such oligonucleotides may be incorporated into reverse transcription primers, PCR primers, or portions of sequencing adapters in preparing sequencing libraries. The resulting sequencing libraries can be used for accurate sequencing, including DNA or RNA counting and mutation detection. Methods and kits for preparing sequencing adapters and sequencing libraries are also provided.
The present disclosure provides oligonucleotides that comprise semi-random barcode sequences. Such oligonucleotides may be incorporated into reverse transcription primers, PCR primers, or portions of sequencing adapters in preparing sequencing libraries. The resulting sequencing libraries can be used for accurate sequencing, including DNA or RNA counting and mutation detection. Methods and kits for preparing sequencing adapters and sequencing libraries are also provided.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Diagnostic preparations for medical use, namely,
preparations used for estimating and predicting time to
delivery of a child. Medical device test kit to determine ruptured fetal
membranes through detection of amniotic fluid in vaginal
secretions.
This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
